ATE362360T1 - Hemmer des phosphattransports - Google Patents

Hemmer des phosphattransports

Info

Publication number
ATE362360T1
ATE362360T1 AT02806234T AT02806234T ATE362360T1 AT E362360 T1 ATE362360 T1 AT E362360T1 AT 02806234 T AT02806234 T AT 02806234T AT 02806234 T AT02806234 T AT 02806234T AT E362360 T1 ATE362360 T1 AT E362360T1
Authority
AT
Austria
Prior art keywords
phosphate transport
transport inhibitors
lower alkyl
substituted
alkyl group
Prior art date
Application number
AT02806234T
Other languages
English (en)
Inventor
Thomas Jozefiak
Cecilia Bastos
Andrew Papoulis
Stephen Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE362360T1 publication Critical patent/ATE362360T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02806234T 2001-12-26 2002-12-24 Hemmer des phosphattransports ATE362360T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34466001P 2001-12-26 2001-12-26
US37164902P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
ATE362360T1 true ATE362360T1 (de) 2007-06-15

Family

ID=26994039

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06077276T ATE464905T1 (de) 2001-12-26 2002-12-24 Phosphattransporthemmer
AT02806234T ATE362360T1 (de) 2001-12-26 2002-12-24 Hemmer des phosphattransports

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06077276T ATE464905T1 (de) 2001-12-26 2002-12-24 Phosphattransporthemmer

Country Status (7)

Country Link
US (2) US7119120B2 (de)
EP (2) EP1815860B1 (de)
JP (2) JP4610900B2 (de)
AT (2) ATE464905T1 (de)
AU (1) AU2002367396A1 (de)
DE (2) DE60236117D1 (de)
WO (1) WO2003057225A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20060160856A1 (en) * 2002-09-05 2006-07-20 Dahl Bjarne H Diarylurea derivatives and their use as chloride channel blockers
EP1398029A1 (de) * 2002-09-10 2004-03-17 LION Bioscience AG 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
US7491718B2 (en) * 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
WO2004037274A1 (en) * 2002-10-22 2004-05-06 Genzyme Corporation Amine polymers for promoting bone formation
DE10257357A1 (de) 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Benzaldehyde
WO2005118538A2 (en) 2004-04-20 2005-12-15 Amgen, Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
EP1839655A1 (de) * 2005-01-20 2007-10-03 Shionogi Co., Ltd. Ctgf-expressionshemmer
WO2007022445A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20080069860A1 (en) * 2005-08-17 2008-03-20 Allison Wren Hyperphosphatemia in domestic animals: compositions and methods of treatment
DE102005044156A1 (de) * 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate
GB0526255D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US20100135950A1 (en) * 2006-07-05 2010-06-03 Genzyme Corporation Iron(II)-Containing Treatments for Hyperphosphatemia
EP2433496A1 (de) * 2007-05-08 2012-03-28 Burnham Institute for Medical Research Nicht gewebespezifische Alkali-Phosphat-Hemmer und deren Verwendung zur Behandlung von Gefäßverkalkungen
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
WO2009146875A1 (en) * 2008-06-03 2009-12-10 Fresenius Medical Care Deutschland Gmbh Pharmaceutical compositions comprising gamma secretase modulators
HUE053352T2 (hu) 2008-06-09 2021-06-28 Univ Muenchen Ludwig Maximilians Új hatóanyagok fehérje-aggregációval kapcsolatos betegségeknél és/vagy neurodegeneratív betegségeknél szerepet játszó fehérjék aggregációjának gátlására
EP2303013A1 (de) * 2008-07-07 2011-04-06 Fasgen, Inc. Neuartige verbindungen, pharmazeutische zusammensetzungen damit, verfahren zu ihrer anwendung und verfahren zu ihrer herstellung
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
CA2977001C (en) 2009-01-26 2018-08-14 Opko Ireland Global Holdings, Ltd. Phosphate management with small molecules
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
US8921343B2 (en) * 2010-03-05 2014-12-30 Duophos Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport
CA2798081C (en) 2010-05-12 2024-02-13 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
JP5827328B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
ES2547890T3 (es) 2010-07-07 2015-10-09 Ardelyx, Inc. Compuestos y métodos para inhibir el transporte de fosfato
JP5827327B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
JP6058557B2 (ja) 2011-01-26 2017-01-11 ザフゲン，インコーポレイテッド テトラゾール化合物ならびにその作製方法および使用方法
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
KR20140053013A (ko) 2011-05-06 2014-05-07 자프겐 인크. 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
EA025526B1 (ru) 2011-05-06 2017-01-30 Зафджен Инк. Частично насыщенные трициклические соединения и способы их получения и применения
AU2013209723B2 (en) 2012-01-18 2016-11-24 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
EP2925737B1 (de) 2012-11-05 2017-06-14 Zafgen, Inc. Tricyclische verbindungen zur verwendung bei der behandlung und/oder kontrolle von adipositas
KR20230132619A (ko) 2013-04-12 2023-09-15 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
CN103467452B (zh) * 2013-09-11 2015-11-18 陕西理工学院 一种苯甲酰胺类化合物及其应用
CN106008360B (zh) * 2016-08-11 2018-10-16 华南农业大学 一种对氨基苯磺酰咪唑及其制备方法
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EP3558992A4 (de) 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. Aktivator von trek (twik-assoziierten k+ kanälen)-kanälen
EP3565811A1 (de) 2017-01-09 2019-11-13 Ardelyx, Inc. Inhibitoren des nhe-vermittelten antiports
AU2018205400B2 (en) 2017-01-09 2022-07-14 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
US12016834B2 (en) 2017-08-03 2024-06-25 Georgetown University Small molecule inhibitors of SLC25A1
WO2019142192A1 (en) 2018-01-17 2019-07-25 Gavish-Galilee Bio Applications Ltd. New methionine metabolic pathway inhibitors
BR112020014561A2 (pt) * 2018-01-17 2020-12-08 Migal - Galilee Research Institute Ltd. Nibidores inovadores da via metabólica da metionina
CN110305045A (zh) * 2018-03-20 2019-10-08 成都海创药业有限公司 一种酰胺类化合物及其在治疗癌症中的用途
EP4140991B1 (de) * 2018-06-01 2024-05-15 Promega Corporation Biolumineszenz-komplexe aus oplophorus-luciferase-hemmern
CN114026085A (zh) 2019-04-11 2022-02-08 安吉昂生物医药公司 (e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式
US20220323389A1 (en) * 2019-08-26 2022-10-13 Georgetown University Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
WO2023219127A1 (ja) * 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002465A1 (en) 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
KR100189863B1 (ko) 1993-12-27 1999-06-01 나이또 하루오 안트라닐산 유도체
AU706262B2 (en) 1995-10-23 1999-06-10 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
EP1005347A4 (de) 1997-08-06 2002-08-28 Smithkline Beecham Corp Antagonisten der rezeptoren der monozyten makrophagen zur verwendung im behandlung kardiovaskuläre erkrankungen
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
JP3972163B2 (ja) * 1999-06-18 2007-09-05 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
AR030911A1 (es) 1999-07-20 2003-09-03 Smithkline Beecham Corp Uso de n-aril-2-sulfonamidobenzamidas para la manufactura de un medicamento para el tratamiento de la insuficiencia renal cronica y composiciones farmaceuticas
WO2001082924A1 (en) 2000-05-02 2001-11-08 Smithkline Beecham Corporation Phosphate transport inhibitors
IL152587A0 (en) 2000-05-12 2003-05-29 Smithkline Beecham Corp Phosphate transport inhibitors
WO2002028353A2 (en) * 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors

Also Published As

Publication number Publication date
EP1815860A3 (de) 2007-11-21
US7119120B2 (en) 2006-10-10
EP1815860A2 (de) 2007-08-08
DE60236117D1 (de) 2010-06-02
EP1465638B1 (de) 2007-05-16
US20040019113A1 (en) 2004-01-29
JP2005514413A (ja) 2005-05-19
EP1465638A2 (de) 2004-10-13
JP2010132674A (ja) 2010-06-17
DE60220188D1 (de) 2007-06-28
EP1815860B1 (de) 2010-04-21
WO2003057225A2 (en) 2003-07-17
JP4610900B2 (ja) 2011-01-12
AU2002367396A1 (en) 2003-07-24
DE60220188T2 (de) 2008-01-24
ATE464905T1 (de) 2010-05-15
WO2003057225A3 (en) 2004-04-08
US20070021509A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
ATE362360T1 (de) Hemmer des phosphattransports
DE69221794D1 (de) 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
BR9900177A (pt) Inibidores de metaloprotease.
NO20034595L (no) Kinolin- og kinazolinderivater med azolylgruppe
DK0695293T3 (da) 10,11-methanodibenzosuberanderivater anvendt som kemosensibiliserende midler
IT1290823B1 (it) Idrossifeniltriazine
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
ATE172452T1 (de) Bicyclische stichstoff enthaltende derivate als prolyl-endopeptidase inhibitoren
PT1044186E (pt) Composto 2-benzilamino-2-fenil-acetamida substituidos
DE69808099D1 (de) Substituierte 6-alkylphenanthridine
FI20001593A0 (fi) Comt-entsyymiä inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
DE60111228D1 (de) Heteropolycyclische inhibitoren
ATE67159T1 (de) Biozide zusammensetzung.
DK0806413T3 (da) 2-substituerede viatmin D3-derivater
ATE376830T1 (de) Benzo(b(thiophenderivate und verfahren zu deren herstellung
ES2191763T3 (es) Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico.
DK1140942T3 (da) Prenyltransferaseinhibitorer
ATE413174T1 (de) Nicht-nucleoside revers-transcriptase inhibitoren
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
ATE430476T1 (de) Schlammbehandlung
EP1033130A4 (de) Hemmer der urokinase produktion, hemmer der angiogenese und verfahren zur vorbeugung oder behandlung unter deren verwendung
EA199800931A1 (ru) Способ получения ингибиторов фосфодиэстеразы iv
MXPA03005556A (es) Derivados de 1,1-dioxo-1,2-benzotiacina-3-carboxamidas, metodo para prepararlos y composiciones farmaceuticas que los contienen.
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties